EG
EGRX.US Eagle Pharmaceuticals Inc
- Market cap
- USD 3.29M
- P/E
- 0.2x
- P/B
- 0.16x
- ROE
- 8.7%
- Dividend yield
- 53.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is EGRX.US undervalued?
Graham numberThe Graham number of Eagle Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eagle Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Eagle Pharmaceuticals Inc yet.
Eagle Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of …
Full company profileEagle Pharmaceuticals Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eagle Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 13.7M | 19.1M | 66.2M | 189M | 237M | 213M | 196M | 188M | 172M | 317M | 262M |
| Gross Profit | 6.30M | 7.39M | 50.6M | 134M | 180M | 151M | 135M | 142M | 129M | 222M | 194M |
| Operating Income | -8.46M | -18.8M | 2.56M | 53.4M | 74.0M | 36.6M | 21.8M | 33.0M | 2.77M | 81.0M | 33.0M |
| EBITDA | -8.41M | -18.8M | 2.70M | 55.0M | 77.8M | 40.4M | 29.3M | 30.0M | 847K | 77.5M | 67.3M |
| Net Income | -6.05M | -18.0M | 2.57M | 81.5M | 51.9M | 31.9M | 14.3M | 12.0M | -8.63M | 35.6M | 21.8M |
| EPS | -0.57 | -1.81 | 0.16 | 4.96 | 3.27 | 2.09 | 1.01 | 0.87 | -0.66 | 2.73 | 1.66 |
| Balance Sheet | |||||||||||
| Total Assets | 18.1M | 53.4M | 125M | 214M | 270M | 239M | 255M | 253M | 254M | 406M | 405M |
| Total Liabilities | 16.0M | 20.3M | 34.3M | 62.3M | 90.9M | 77.8M | 75.4M | 67.2M | 77.3M | 173M | 153M |
| Shareholders' Equity | 2.05M | 33.1M | 90.3M | 151M | 179M | 161M | 179M | 186M | 176M | 234M | 252M |
| Cash & Short-term Investments | 10.5M | 42.7M | 79.1M | 52.8M | 115M | 78.8M | 110M | 103M | 97.7M | 55.3M | 15.4M |
| Total Debt | - | - | - | - | 47.8M | 44.4M | 38.6M | 38.2M | 29.8M | 67.8M | 71.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.88M | -13.8M | -9.72M | 53.2M | 58.9M | 52.4M | 56.0M | 49.5M | 28.2M | 50.7M | -67.3M |
| Capital Expenditure | 40.5K | 46.0K | 1.88M | 20.7M | 5.19M | 133K | 777K | 747K | 323K | 178K | 128K |
| Free Cash Flow | -5.92M | -13.9M | -11.6M | 32.5M | 53.7M | 52.3M | 55.2M | 48.8M | 27.9M | 50.5M | -67.4M |
| Ratios | |||||||||||
| ROE | -294.5% | -54.3% | 2.8% | 53.9% | 29.0% | 19.8% | 8.0% | 6.4% | -4.9% | 15.3% | 8.7% |
| ROA | -33.4% | -33.7% | 2.1% | 38.1% | 19.2% | 13.4% | 5.6% | 4.7% | -3.4% | 8.8% | 5.4% |
| Net Profit Margin | -44.2% | -94.1% | 3.9% | 43.0% | 21.9% | 15.0% | 7.3% | 6.4% | -5.0% | 11.3% | 8.3% |
| Debt to Equity | - | - | - | - | 0.27x | 0.28x | 0.22x | 0.21x | 0.17x | 0.29x | 0.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eagle Pharmaceuticals Inc dividends
- Dividend yield
- 53.11%
- Forward dividend
- -
- Payout ratio
- 4.9%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | USD 1.75M | 0.13 | 4.9% |
| 2021 | USD 2.40M | 0.18 | - |
| 2020 | USD 3.65M | 0.27 | 30.5% |
| 2019 | USD 260K | 0.02 | 1.8% |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
| 2014 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Eagle Pharmaceuticals Inc
- Insiders 0.00%
- Institutions 43.35%
- Public & others 56.65%
- Shares outstanding 13.2M
- Free float 7.39M
Top funds holding EGRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BSF Systematic US Eq Abs Ret A2 USD | 57.1K | 0.43% | -2.23% | Dec 2025 |
| BlackRock Diversified Equity Alpha Inst | 2.31K | 0.02% | 0.00% | Jun 2026 |
| Diversified Equity Alpha Fund F | 221.00 | 0.00% | -0.45% | Jun 2026 |
| BlackRock LifePath Dynamic 2040 Fund T | 4.00 | 0.00% | 0.00% | Mar 2026 |
Top institutions holding EGRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Stanley-Laman Group Ltd | 12.0K | 0.09% | 0.00% | Mar 2026 |
| Archer Investment Corporation | 350.00 | 0.00% | 0.00% | Jun 2026 |
Eagle Pharmaceuticals Inc company profile
- Company name
- Eagle Pharmaceuticals Inc
- Ticker
- EGRX.US
- Exchange
- USA Stocks
- Listed since
- Feb 12, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 134
- Fiscal year end
- December
- Address
- 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677
- Phone
- 201 326 5300
- Website
- eagleus.com
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Eagle Pharmaceuticals Inc management
4- Mr. Michael GravesCEO & Chairman · born 1963
- Mr. Christopher Stanley Krawtschuk CPACFO and Principal Financial & Accounting Officer · born 1973
- Mr. Daniel O'ConnorExecutive VP, Chief Strategy Officer & Head of Corporate Development · born 1980
- Dr. Valentin R. Curt M.D.Senior Vice President of Clinical Drug Development